Portal de Periódicos da CAPES

Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up

2012; Elsevier BV; Volume: 23; Issue: 9 Linguagem: Inglês

10.1093/annonc/mds177

1569-8041

P Colombat, Nicole Brousse, Gilles Salles, Franck Morschhauser, Pauline Brice, Pierre Soubeyran, Vincent Delwail, Éric Deconinck, Corinne Haïoun, C. Foussard, Catherine Sebban, H. Tilly, Catherine Thiéblemont, Laurence Bergougnoux, F. Lazreg, P. Solal-Céligny,

Immune Cell Function and Interaction

The purpose of this study was to report long-term results of rituximab induction monotherapy in patients with low-tumor-burden follicular lymphoma (LTBFL).